Tune Therapeutics
Tune develops TEMPO epigenetic regulation to activate or silence gene expression without cutting or changing the DNA sequence. Epigenetic modulation should be distinguished from sequence editing and permanent DNA insertion.
Corporate information
- Company entity
- Tune Therapeutics
- Headquarters / principal office
- Seattle, WashingtonSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2020 ↗
- Ownership / capital status
- PrivateSeries B (historical disclosure: over USD175 million) ↗
- Official corporate reference
- https://tunetx.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2025 · Series B · Over USD 175 million ↗
The source reports more than USD175 million; this lower bound is not entered as an exact sortable amount.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Tune develops TEMPO epigenetic regulation to activate or silence gene expression without cutting or changing the DNA sequence. Epigenetic modulation should be distinguished from sequence editing and permanent DNA insertion.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Corporate website links to the company LinkedIn page
- Company-managed LinkedIn profile — self-reported location
- Corporate ownership / financing disclosure